BackAcasti Pharma Overview

Acasti Pharma Receivables

Track Acasti Pharma's receivables ($20K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$20000.00
84.13% YoYΔ $-106000.00 vs prior year quarter

Peer average

Loading

Acasti Pharma Receivables History

Loading

Acasti Pharma vs. peers: Receivables Comparison

Loading

Acasti Pharma Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Acasti Pharma (ACST) FAQ

The latest receivables for ACST is $20K as of March 2026. That compares with $130K in the prior-year period — down 84.1% year over year. Investors often review this figure alongside Acasti Pharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, ACST's receivables moved from $130K to $20K — a 84.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Acasti Pharma's operating scale or balance-sheet position.

A receivables figure of $20K for ACST is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting ACST's receivables ($20K), review year-over-year change from $130K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Acasti Pharma's receivables against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.